Tecartus (brexucabtagene autoleucel), Kite Pharma’s CAR T-cell therapy for mantle cell lymphoma, is on track to becoming approved in the EU for an expanded indication – acute lymphoblastic leukemia (ALL).
The European Medicines Agency’s human medicines committee, the CHMP, recommended in favor of authorizing the new indication last week. If...






